De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis

Table 1 Baseline characteristics of patients with HBV-related decompensated cirrhosis n (%)

Variables	LAM + ADV (n = 45)	ETV (n = 45)	t	χ2	P value
Age (yr)	53.1 ± 8.8	53.2 ± 7.4	0.23		> 0.05
Male/female	29/16	28/17		3.10	> 0.05
HBV DNA (log10 copy/mL)	6.56 ± 1.13	6.61 ± 1.15	0.33		> 0.05
ALT (U/L)	98.1 ± 21.6	99.8 ± 17.2	0.23		> 0.05
TBil (μmol/L)	51.6 ± 8.9	49.2 ± 6.8	0.31		> 0.05
Alb (g/L)	29.2 ± 0.7	29.5 ± 1.2	0.24		> 0.05
PT (s)	16.3 ± 2.3	16.5 ± 1.9	0.21		> 0.05
CTP score	8.4 ± 1.7	8.6 ± 2.1	0.16		> 0.05
MELD score	13.7 ± 3.5	12.9 ± 6.7	0.25		> 0.05
HBeAg positive rate	23 (51.1)	22 (48.9)		2.13	> 0.05
Ascites	22 (48.9)	21 (46.7)		2.46	> 0.05
HE	6 (13.3)	7 (15.5)		3.13	> 0.05
UGB	9 (22.2)	8 (17.8)		3.35	> 0.05

ALT: Alanine aminotransferase; TBil: Total bilirubin; Alb: Albumin; PT: Prothrombin time: CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease; HE: Hepatic encephalopathy; UGB: Upper gastrointestinal bleeding; HBeAg: Hepatitis B e antigen.

Table 2 Comparison of changes in hepatic function

Characteristics	LAM + ADV combination group			ETV monotherapy group
	0 wk	48 wk	96 wk	0 wk	48 wk	96 wk
Alb (g/L)	29.2 ± 0.7	32.2 ± 0.5	36.7 ± 0.2a	28.9 ± 1.2	31.9 ± 0.4	36.4 ± 0.6a
TBil (μmol/L)	51.6 ± 8.9	30.8 ± 7.5	19.1 ± 6.2a	47.2 ± 6.8	31.6 ± 6.8	18.2 ± 3.9a
ALT (U/L)	98.1 ± 21.6	56.1 ± 21.3	34.7 ± 12.8a	99.8 ± 17.2	54.2 ± 15.7	32.5 ± 11.5a
PT (s)	16.3 ± 2.3	14.3 ± 1.6	12.6 ± 2.1a	16.5 ± 1.9	13.8 ± 2.0	12.9 ± 3.7a
CTP score	8.4 ± 1.7	6.8 ± 1.9	5.5 ± 3.7a	8.6 ± 2.1	6.7 ± 2.5	5.7 ± 1.3a
MELD score	13.7 ± 3.5	9.8 ± 3.1	7.6 ± 1.8a	12.9 ± 6.7	9.6 ± 4.3	7.9 ± 2.3a

^aP < 0.05 vs baseline. ALT: Alanine aminotransferase; TBil: Total bilirubin; Alb: Albumin; PT: Prothrombin time: CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease; LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir.